Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Czarnecki

Sports Medicine Woburn, MA Medical Doctor

NPI 1639147374 CMS profile 300766

200 Unicorn Park Dr, Suite 201, Woburn, MA 01801

Open in the dashboard

General payments

$92,531

123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Czarnecki of Woburn, MA is reported in the CMS Open Payments database as having received $92,531 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,267 18
2024 General $12,970 14
2023 General $20,868 19
2022 General $12,590 17
2021 General $8,229 16
2020 General $572 13
2019 General $9,035 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Czarnecki
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Joseph Czarnecki were reported at $28,267. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Joseph Czarnecki Sports Medicine median Middle half National median
2019 $9,035 $1,176 $199–$4,249 $163
2020 $572 $708 $96–$2,890 $114
2021 $8,229 $1,213 $152–$3,994 $132
2022 $12,590 $1,230 $159–$3,998 $149
2023 $20,868 $584 $146–$2,836 $160
2024 $12,970 $628 $163–$3,168 $164
2025 $28,267 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vericel Corporation $80,411 56 payments
  2. Linvatec Corporation $10,712 15 payments
  3. Flexion Therapeutics, Inc. $683 25 payments
  4. Smith+Nephew, Inc. $183 4 payments
  5. Stryker Corporation $173 3 payments
  6. Bioventus LLC $128 6 payments
  7. Ferring Pharmaceuticals Inc. $94 6 payments
  8. Pacira Pharmaceuticals Incorporated $66 3 payments
  9. DePuy Synthes Sales Inc. $35 2 payments
  10. Moximed, Inc $22 1 payment
  11. Other $23 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for serving as faculty or as a speaker for a medical education program $42,573 18 payments
  2. Consulting Fee $35,748 14 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $6,750 1 payment
  4. Food and Beverage $3,399 77 payments
  5. Honoraria $2,275 3 payments
  6. Travel and Lodging $1,610 8 payments
  7. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $176 2 payments
Products named General payments · program years 2019–2025
  1. MACI Orthopedics $70,718 50 payments
  2. LINVATEC KNEE PRESERVATION SYSTEM $9,131 6 payments
  3. MACI Cellular Therapy $5,914 3 payments
  4. LINVATEC HIP PRESERVATION SYSTEM $1,576 7 payments
  5. Zilretta $683 25 payments
  6. MACI Cellular Therapy $232 2 payments
  7. IVY AIR $155 2 payments
  8. ICONIX $155 2 payments
  9. CINCHLOCK SS $155 2 payments
  10. LINVATEC SHOULDER ARTHROSCOPY $127 2 payments
  11. Other $988 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$104,226

Of which drugs: $13,278

Medicare patients

338

Average age 73

Services billed

2,005

189 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 69%
Ischemic heart disease 22%
Chronic kidney disease 22%
Diabetes 20%
Osteoporosis 18%
Depression 17%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 11 672 $9,312
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 12 17 $1,578
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 105 259 $197

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record